Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (6,961)	$ (9,705)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Depreciation and amortization	746	678
Amortization of convertible notes debt discount		677
Loss on extinguishment of term loan	728
Stock‑based compensation expense	1,752
Change in fair value of warrant liability		(51)
Change in contingent consideration	983	957
Accrued interest on notes payable and convertible notes payable	24	287
Amortization of debt issuance costs	41	36
Provision for doubtful accounts	193	(3)
Changes in operating assets and liabilities:
Accounts receivable	(3,256)	2,464
Other current assets	1,068	(85)
Other long-term assets and liabilities	224	(82)
Accounts payable and other accrued liabilities	(5,744)	857
Deferred revenue	(1,124)	(567)
Net cash and cash equivalents and restricted cash used in operating activities	(11,326)	(4,537)
Cash flows from investing activities
Purchases of property and equipment	(466)	(98)
Patent costs and intangible asset acquisition, net	(50)	(44)
Payment to acquire Oncimmune assets		(250)
Net cash and cash equivalents and restricted cash used in investing activities	(516)	(392)
Cash flows from financing activities
Proceeds from exercise of stock options	475	11
Proceeds from term loan and notes payable	30,000	6,409
Repayment of term loan and notes payable	(25,416)
Payment of debt issuance costs	(108)
Net cash and cash equivalents and restricted cash provided by financing activities	4,951	6,420
Net (decrease) increase in cash and cash equivalents and restricted cash	(6,891)	1,491
Cash, cash equivalents, and restricted cash ‑ beginning of period	62,306	5,468
Cash, cash equivalents, and restricted cash ‑ end of period	$ 55,415	$ 6,959